Skip to main content
. 2023 May 22;136(14):1690–1698. doi: 10.1097/CM9.0000000000002696

Table 1.

Baseline characteristics of participants infected with H. pylori in initial eradication therapy.

Characteristics A group (N = 100) B group (N = 100) C group (N = 100) Statistics P values
Age (years), mean ± SD 44.36 ± 12.40 46.49 ± 11.60 44.29 ± 12.10 0.849* 0.429
Sex, male/female 42/58 41/59 47/53 0.842 0.670
BMI (kg/m2), mean ± SD 22.56 ± 3.00 23.26 ± 2.90 23.22 ± 3.37 1.620* 0.200
Smoking, n (%) 8.586 0.072
Yes 7 (7.0) 13 (13.0) 21 (21.0)
No 85 (85.0) 80 (80.0) 71 (71.0)
Stop smoking 8 (8.0) 7 (7.0) 8 (8.0)
Drinking, n (%) 1.721 0.785
Yes 22 (22.0) 26 (26.0) 21 (21.0)
No 73 (73.0) 69 (69.0) 71 (71.0)
Stop drinking 5 (5.0) 5 (5.0) 8 (8.0)
Drinking water source, n (%) 2.027 0.409
City water 96 (96.0) 94 (94.0) 98 (98.0)
Non-city water 4 (4.0) 6 (6.0) 2 (2.0)
Degree of education, n (%) 0.360 0.875
University and above 57 (57.0) 53 (53.0) 56 (56.0)
High school and below 43 (43.0) 47 (47.0) 44 (44.0)
Diabetes, n (%) 1.097 0.684
Yes 3 (3.0) 4 (4.0) 6 (6.0)
No 97 (97.0) 96 (96.0) 94 (94.0)
Diseases, n (%) 8.812 0.058
Chronic gastritis 49 (49.0) 48 (48.0) 49 (49.0)
Peptic ulcer 1 (1.0) 1 (1.0) 8 (8.0)

A group: Berberine triple therapy; B group: Vonoprazan quadruple therapy; C group: Rabeprazole quadruple therapy. Data are presented as the mean ± SD; *F value; χ2 value. BMI: Body mass index; SD: Standard deviation; H. pylori: Helicobacter pylori.